Suboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia: What Is the Optimal Strategy?

Jabbour, Elias; Cortes, Jorge E.; Kantarjian, Hagop M.
February 2009
Mayo Clinic Proceedings;Feb2009, Vol. 84 Issue 2, p161
Academic Journal
Treatment responses to imatinib vary among patients with chronic myeloid leukemia (CML), and definitions of treatment failure and suboptimal response have been published. This article discusses monitoring and treatment of patients with CML after failure of or suboptimal response to imatinib therapy. We reviewed articles listed on PubMed from January 1, 2002, to July 31, 2008, and abstracts from the 2007 Annual Meeting of the American Society of Hematology. Search terms used were chronic myeloid/myelogenous leukemia, imatinib, and BCR-ABL. To enable early recognition of suboptimal responses, patients should be frequently monitored according to published guidelines, including cytogenetic analysis every 6 months until a complete response is achieved and molecular monitoring every 3 months from the start of therapy or monthly if an increasing BCR-ABL1 transcript level is detected. Mutational analysis of BCR-ABL1 may assist with treatment selection. A recent survey suggests that a notable proportion of physicians do not follow treatment guidelines and that broader communication is required. Recent recommendations state that, in patients whose response to Imatinib at 400 mg/d is suboptimal, the dose should be increased, whereas alternative therapies, such as dasatinib, nilotinib, and aliogeneic stem cell transplant (in eligible patients), and imatinib dose escalation should be considered after imatinib failure. However, clinical data are lacking to confirm this sequence of treatments, and introducing alternative therapies at an earlier stage of treatment, for example, after a suboptimal response, may produce better long-term outcomes in a higher proportion of patients. Patient and disease characteristics should be carefully considered to optimize treatment strategy for CML.


Related Articles

  • Chronic Myelocytic Leukemia -- Part II: Approaches to and Molecular Monitoring of Therapy. Randolph, Tim R. // Clinical Laboratory Science;Winter2005, Vol. 18 Issue 1, p49 

    Focuses on a study which presented the approaches to and molecular monitoring of therapy for chronic myelocytic leukemia (CML). Evolution of the therapeutic approaches for the disease; Effectiveness of the Imatinib therapy as measured by molecular methods; Strategies for the management of CML...

  • What role does imatinib play in CML after the approval of dasatinib and nilotinib for newly diagnosed CML? Talpaz, Moshe; Deininger, Michael // Hem/Onc Today;2/25/2011, Vol. 12 Issue 4, p11 

    The article presents the views of U.S. medical experts Moshe Talpaz and Michael Deininger on the role that imatinib and nilotinib play in the treatment of newly diagnosed chronic myelogenous leukemia (CML).

  • Delivery of two normal twins exposed to imatinib and nilotinib during the first trimester of pregnancy in a woman with chronic myeloid leukemia. Mseddi, S. Hadiji; Kallel, F.; Amouri, H.; Affes, H.; Mdhaffar, M.; Elloumi, M. // Journal of Hematological Malignancies;Sep2012, Vol. 2 Issue 3, p74 

    We report here the case of a 35-year-old woman. She was diagnosed with Philadelphia chromosome-positive chronic myeloid leukemia. Because of primary infertility, she received imatinib without contraception. Complete cytogenetic response was not obtained with 800 mg/day. As a result, the patient...

  • Imatinib gives impressive long-term survival in CML patients.  // British Journal of Hospital Medicine (17508460);Feb2009, Vol. 70 Issue 2, p71 

    The article reports on the "International Randomized Interferon VersusSTI571," (IRIS) study done to test the effectiveness of Glivec (imatinib) in the treatment of Philadelphia chromosome positive (Ph+) chronic myeloid Leukaemia (CML). The study states that, 86% of patients suffering from the...

  • IMATINIB.  // Complete Guide to Prescription & Nonprescription Drugs 2012;2012, p438 

    The article presents information on imatinib, an antineoplastic agent, including its dosage, usage, adverse reactions or side effects, precautions when administering, and possible interaction with other drugs and substances.

  • IMATINIB.  // Complete Guide to Prescription & Nonprescription Drugs 2012;2007, p436 

    The article presents information on imatinib, an antineoplastic agent used for the treatment of chronic myeloid leukemia. The dosage and usage information is provided. The possible adverse reactions or side effects of the drug, warnings, and precautions are discussed. Possible interaction of the...

  • Do we have to kill the last CML cell? Ross, D. M.; Hughes, T. P.; Melo, J. V. // Leukemia (08876924);Feb2011, Vol. 25 Issue 2, p193 

    Previous experience in the treatment of chronic myeloid leukaemia (CML) has shown that the achievement of clinical, morphological and cytogenetic remission does not indicate eradication of the disease. A complete molecular response (CMR; no detectable BCR-ABL mRNA) represents a deeper level of...

  • Novartis: market experience will help Tasigna.  // PharmaWatch: Cancer;Jan2007, Vol. 6 Issue 1, p4 

    The article reports on the completion of Novartis AG on the regulatory submissions for chronic myeloid leukemia (CML) drug Tasigna. The drug is created as follow-up for the company's currently in gold standard for the treatment of CML, the Gleevec drug, which had displayed some weaknesses in...

  • Dasatinib in the Treatment of Chronic Myeloid Leukemia. Gora-Tybor, Joanna; Robak, Tadeusz // Current Signal Transduction Therapy;Jan2011, Vol. 6 Issue 1, p99 

    The recognition that the BCR-ABL gene and corresponding protein with deregulated tyrosine kinase (TK) activity is crucial for malignant transformation in chronic myeloid leukemia (CML), led to the synthesis of the small-molecule drugs designed to interfere with BCR-ABL TK activation. The first...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics